Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05421975
Other study ID # STH21669
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 28, 2021
Est. completion date February 1, 2024

Study information

Verified date April 2023
Source Sheffield Teaching Hospitals NHS Foundation Trust
Contact UoS MRI unit
Phone 01142159595
Email mriresearch@sheffield.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Sarcoidosis is a condition where inflamed cells clump together to form granulomas, which can lead to inflammation or scarring. It can affect any organ of the body, but most commonly affects the lungs. Symptoms can be highly variable, and some patients have no symptoms where as others may develop fatigue or breathlessness. The causes of sarcoidosis are poorly understood. It commonly affects adults in their 30's or 40's. Some patients present with symptoms suggestive of involvement in the airways, such as cough. Inhalers containing steroid are commonly used, but there is a poor understanding of which patients may benefit. Part of the problem is the lack of a sensitive way of measuring these effects and knowledge of how sarcoidosis affects the airways physiologically. The investigators would like to know more about the disease process of sarcoidosis, particularly where it involves the airways. This study will use a number of techniques in order to better understand to disease process. In order to assess whether sarcoidosis produces changes in airway ventilation (and whether these changes are stable or change over a short time period). This pilot study aims to recruit 6 patients who will have magnetic resonance imaging (MRI) with inhaled xenon gas. During this technique, xenon and nitrogen mixture is inhaled and during a subsequent breath-hold, images of the lungs are taken. This creates a detailed view of the lung airway tree, to explore how the disease affects the airways and deeper lung tissue. This technique will be used alongside lung function tests, commonly performed in the laboratory setting and cardiopulmonary exercise testing, to see what happens in the lungs of this group of patients when they reach peak exercise capacity.


Recruitment information / eligibility

Status Recruiting
Enrollment 6
Est. completion date February 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Clinical diagnosis of sarcoidosis - Sarcoidosis clinician diagnoses airways involvement - Aged 18 and above Exclusion Criteria: - Current combustible cigarette or electronic cigarette user - Significant doubt over the diagnosis of sarcoidosis - Asthma or other airways disease, requiring regular inhaler use - Contraindication to MRI identified on safety questionnaire - Recent COVID-19 infection (lateral flow or PCR swab positive within the last 28 days) or ongoing symptoms from COVID-19

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom University MRI Unit Sheffield

Sponsors (1)

Lead Sponsor Collaborator
Sheffield Teaching Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Does endobronchial sarcoidosis produce changes, which are appreciable on ventilation MRI and are they temporally stochastic or deterministic. (1) Ventilation defect percentage (VDP) - a measure of amount of the lung which goes unventilated 12 weeks
Primary Does endobronchial sarcoidosis produce changes, which are appreciable on ventilation MRI and are they temporally stochastic or deterministic.(2) Ventilation Coefficient of variation (CV) - a measure of ventilation heterogeneity 12 weeks
Primary Does endobronchial sarcoidosis produce changes, which are appreciable on ventilation MRI and are they temporally stochastic or deterministic. (3) Apparent diffusion coefficient (ADC) and mean linear intercept (LmD) - measurements of the Brownian motion of gas in the acinar airways and surrogate measures of acinar integrity. 12 weeks
Primary Does endobronchial sarcoidosis produce changes, which are appreciable on ventilation MRI and are they temporally stochastic or deterministic. (4) Red blood cell to tissue plasma ratio (RBC:TP) - a measure of the efficiency of gas exchange across the alveoli into the blood. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04008069 - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00326534 - Rickettsial Genesis to Sarcoidosis in Denmark N/A
Completed NCT00373555 - Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis N/A
Completed NCT00274352 - A Study of Adalimumab to Treat Sarcoidosis of the Skin Phase 2
Recruiting NCT00470327 - A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Completed NCT00512967 - The Occurence of Inflammation and Oxidative Stress in Lung Diseases N/A
Recruiting NCT01745237 - Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Completed NCT00369980 - Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Completed NCT04156789 - Obstructive Sleep Apnoea in Sarcoidosis
Recruiting NCT02916459 - EBUS-TBNA vs Flex 19G EBUS-TBNA N/A
Recruiting NCT02827734 - Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Completed NCT02546388 - Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01139710 - Sarcoidosis-associated Pulmonary Hypertension N/A
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4
Completed NCT00555347 - Use of Armodafinil for Fatigue in Sarcoidosis Phase 2/Phase 3